Summit Therapeutics PLC
$18.08
(as of Jun 3, 9:33 AM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Summit Therapeutics PLC
Stock Price
$18.08
Ticker Symbol
SMMT
Exchange
NASDAQ
Industry Information for Summit Therapeutics PLC
Sector
Healthcare
Industry
Biotechnology
Company Description for Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Fundamentals for Summit Therapeutics PLC
Market Capitalization
$17,424,003,072
EBITDA
$-210,902,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.31
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
737,680,000
Percent Owned by Insiders
84.36%
Percent Owned by Institutions
12.94%
52-Week High
52-Week Low
Technical Indicators for Summit Therapeutics PLC
Analyst Ratings for Summit Therapeutics PLC
Strong Buy
6
Buy
3
Hold
0
Sell
0
Strong Sell
0
News About Summit Therapeutics PLC
Jun 4, 2025, 7:26 AM EST
We recently published a list of 10 Stocks Leaving Wall Street in The Dust. See more.
Jun 3, 2025, 9:35 AM EST
A downtrend has been apparent in Summit Therapeutics PLC (SMMT) lately with too much selling pressure. See more.
Jun 2, 2025, 11:46 AM EST
Shares of Summit Therapeutics SMMT tanked nearly 31% on Friday after it reported mixed results from the phase III HARMONi study, which evaluated its investigational antibody ivonescimab in certain patients with non-small cell lung cancer (NSCLC).
See more.
Jun 2, 2025, 11:39 AM EST
Drugmakers hope a new class of cancer drugs could unseat Keytruda, the Merck immuno-oncology blockbuster.
See more.